Hana Pharm: 2025 Net Profit Plunges and Dividend Cut, Multiple Governance Non-Compliances Exposed
2025 consolidated revenue increased 6.3% to 239.5B KRW and operating profit rose 2.6% to 25.8B KRW, but net profit plummeted 58.7% to 8.8B KRW from 21.3B KRW in 2024, indicating severe profitability deterioration
Dividend per share halved from 510 KRW in 2024 to 260 KRW in 2025, and dividend yield dropped from 4.61% to 2.2%, reducing shareholder return attractiveness
Only 4 out of 15 core governance indicators were met (26.7% compliance), including failure to send notice 4 weeks before AGM, no electronic voting, lack of outside director evaluation and internal control policies
Major shareholder and related parties hold 57.71% stake, providing stable control, but minority shareholders (41.31%) face potential voting constraints; at the 48th AGM, the reappointment of CEO Choi Tae-hong received only 56% approval with 44% against
Value-up plan announced in April 2026 focuses on R&D and export expansion to improve profitability, but lacks detailed implementation steps and shareholder communication, creating uncertainty
[AI Summary]Hana Pharm faces heightened investment risk due to a sharp net profit decline and dividend cut in 2025, compounded by widespread governance non-compliance. The company's ability to execute its value-up plan and address governance shortcomings will be critical for future stock performance.